OX40 ligand is inhibitory during the effector phase of crescentic glomerulonephritis.

Autor: Odobasic D; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia., Ruth AJ; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia., Oudin V; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia., Kitching AR; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia.; Department of Pediatric Nephrology, Monash Health, Clayton, Victoria, Australia.; Department of Nephrology, Monash Health, Clayton, Victoria, Australia., Holdsworth SR; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Monash Medical Centre, Clayton, Victoria, Australia.; Department of Nephrology, Monash Health, Clayton, Victoria, Australia.

Publikováno v: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2019 Mar 01; Vol. 34 (3), pp. 429-441.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PCN103 HETEROGENEITY IN THE APPROACH TAKEN TO CONDUCTING CHART AUDITS IN AUSTRALIAN HOSPITALS

Autor: O'Leary, BA, Colman, S, Ruth, AJ, Cook, GA

Publikováno v: In Value in Health 2008 11(6):A492-A493

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.